Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to GT200700040ApriorityCriticalpatent/GT200700040A/en
Publication of GT200700040ApublicationCriticalpatent/GT200700040A/en
LA INVENCIÓN SE RELACIONA CON MUTEÍNAS DEL FACTOR VIII QUE ESTÁN LIGADAS COVALENTEMENTE, EN UN SITIO PREDEFINIDO QUE NO ES UNA AMINA DE TERMINAL N, A UNO O MÁS POLÍMEROS BIOCOMPATIBLES TALES COMO POLIETILENGLICOL. LOS CONJUGADOS DE LA MUTEÍNA RETIENEN LA ACTIVIDAD PROCOAGULANTE DEL FVIII Y TIENEN PROPIEDADES FARMACOCINÉTICAS MEJORADAS. T2007THE INVENTION IS RELATED TO MUTEINS OF FACTOR VIII THAT ARE COVALENTLY LINKED, IN A PRE-DEFINED SITE THAT IS NOT A TERMINAL AMINE N, TO ONE OR MORE BIOCOMPATIBLE POLYMERS SUCH AS POLYETHYLENE. THE MUTEINE CONJUGATES WITHDRAW THE PROVIAGULANT ACTIVITY OF FVIII AND HAVE IMPROVED PHARMACOCINETIC PROPERTIES. T2007
GT200700040A2007-05-112007-05-11
MODIFICATION DIRECTED TO THE FVIII SITE
GT200700040A
(en)
Compounds derived from n- (1-4- (1h-pyrazol-5-yl) phthalazine-1-yl) piperidine-4-yl) benzamide; pharmaceutical composition that contains them, useful as antagonist of the hedgehog trajectory, in the treatment of cancer.
NEW DERIVATIVES OF (CONETENSED HETEROCICLO-PIPERIDINE) - (PIPERAZINIL) -1-ALCANONE OR (CONDENSED HETEROCILCO-PIRROLIDINE) - (PIEPRAZINIL) -1-ALCANONA AND ITS USE AS P75 INHIBITORS